EVALUATION OF N-TYPE CA2-GANGLION NEURONS( CHANNEL CURRENTS IN CULTURED RAT SUPERIOR CERVICAL)

Citation
Sj. Stoehr et al., EVALUATION OF N-TYPE CA2-GANGLION NEURONS( CHANNEL CURRENTS IN CULTURED RAT SUPERIOR CERVICAL), Drug development research, 41(2), 1997, pp. 85-90
Citations number
23
Categorie Soggetti
Chemistry Medicinal","Pharmacology & Pharmacy
Journal title
ISSN journal
02724391
Volume
41
Issue
2
Year of publication
1997
Pages
85 - 90
Database
ISI
SICI code
0272-4391(1997)41:2<85:EONCNC>2.0.ZU;2-H
Abstract
Electrophysiological studies of the effects of test compounds on ion c hannel currents have been useful in the identification of novel therap eutic agents. Here, we examined the use of cultured superior cervical ganglion (SCC) neurons as a model system for the electrophysiological evaluation of N-type Ca2+ channels in vitro. As previously reported, C a2+ channel currents in acutely dissociated preparations of SCG neuron s were mainly N-type, as defined by inhibition of Ca2+ channel current with the specific N-type Ca2+ channel blocker, omega-conopeptides GVI A or MVIIA. However, a cultured preparation that could be used over an extended period of time would be more useful for drug discovery since acutely dissociated preparations require daily dissections. We found that with extended time in culture the amplitudes of Ca2+ channel curr ents increased with time. While there was a reduction in the percentag e of N-type Ca2+ channel component, the majority (70%) of Ca2+ channel currents in long-term cultured SCG neurons remained N-type. A portion of the MVIIA-resistant Ca2+ channel current component was blocked by the omega-conopeptide MVIIC and omega-agatoxin IIIA, but not by omega- agatoxin IVA, a pharmacological profile similar to Q-type Ca2+ channel current. These studies suggest that cultured SCG neurons would be use ful for the study of N-type Ca2+ currents even after prolonged time in culture, and may also be used to indicate the selectivity of test com pounds for other Ca2+ channel subtypes. (C) 1997 Wiley-Liss, Inc.